Piper Jaffray On BSX Following Platinum Trial At ACC

Piper Jaffray has issued a report on Boston Scientific Corp BSX after its presentation of the Platinum Trial at the American College of Cardiology. According to the report, "While the solid clinical results were largely expected, it should set the stage for U.S. FDA approval of Promus Element in H1:12. And given the uplift in profitability tied to Promus Element, we should see earnings potential as well." BSX has a Neutral Rating and a $7 Price Target. BSX closed yesterday at $7.23 a share.